innovation.org
Home | About Us | Site Map | Contact Us Search
Impact of Innovation Future of Innovation Stories of Innovation Inside Drug Discovery News Center Tools & Resources
New Medicines in Development
Personalized Medicine in Action
Partnership for Prescription Assistance
In the News

 

February 15, 2014

U.S. FDA Approves BioMarin's Genetic Disorder Drug Vimizim - Reuters

 

February 12, 2014

J&J, Pharmacyclics Drug Wins U.S. Approval for Leukemia - Reuters

 

January 31, 2014

FDA Approves Hetlioz for Sleep Disorder in Fully-Blind Patients - The Wall Street Journal

 

January 28, 2014

Drug Shows Promise in Advanced Prostate Cancer When Used Before Chemotherapy - The New York Times

 

Sign Up for
our Newsletter:

Get our newsletter on the impact of new medicines and updates on what's new in innovation.

 

Advances in Rare Disease Research

The National Institutes of Health Office of Rare Diseases Research has identified close to 7,000 rare diseases, which affect an estimated 25 million people across the country. This population is particularly in need of medicines and other treatments because, as the U.S. Food and Drug Administration estimates, 85-90% of rare diseases are serious or life-threatening. Read more.

 

 

Innovation.Org Highlights a Year of Continued Innovation for Patients

In 2013, biopharmaceutical researchers and their partners from across the healthcare continuum continued to make advances against disease. This month, Innovation.org takes a look back at some of the highlights in drug discovery and development. Read the newsletter.

 

 

Innovation.org Highlights the Nearly 400 Medicines and Vaccines in Testing to Fight Infectious Diseases

America's biopharmaceutical research companies are developing 394 new medicines to combat infectious diseases, including viral infections, bacterial infections, fungal infections and parasitic infections. Read more.

 
 

 

Alzheimer's Disease - The Puzzles, The Partners, The Path Forward

Innovation Insights highlights a recent forum convened by the Alzheimer's Association, the Alzheimer's Drug Discovery foundation, and PhRMA, which provided an opportunity to evaluate the challenges and opportunities in pre-competitive partnerships, clinical trial enrollment and public policy for Alzheimer's disease. Read the newsletter.